ESR1 and breast cancer: Besides, overexpression of CCNA2 also confers poor disease free survival (Fig. S1B, P = 2.433e−06 and Fig. S1C, P = 3.583e−05), relapse free survival (Fig. S1D, P = 2.601e−08) and overall survival (Fig. S1E, P = 2.03e−04 and Fig. S1F, P = 0.038) in ER+ breast cancer cohorts as noted in each figures.